AstraZeneca has announced that its rare disease group Alexion will invest €65m to scale up its biologics manufacturing capacity in Ireland and expand R&D efforts in the region over the next 18 months.
Image credit: Dimitris Barletis / Shutterstock
The money will go towards the installation of new drug substance production equipment and warehousing facilities to support ambient and cold storage at two sites: College Park in Blanchardstown and Monksland Industrial Park in Athlone.
Read more: AstraZeneca acquisition of Alexion gets UK regulation nod
Additionally, a manufacturing sciences and technology lab will be built at College Park to support the scaling up of biologics drug substance manufacturing in the country.
The €65 million investment follows a €341 million investment in the Blanchardstown facility last year to establish a next generation active pharmaceutical ingredient manufacturing unit on the site.
Read more: New material could pave the way for 'electric' medication
Marc Dunoyer, Chief Executive Officer (CEO) of Alexion, stated “We are delighted to be further investing in our facilities in Ireland, an increasingly critical global hub for AstraZeneca operations, to support the continued growth of Alexion’s portfolio of medicines and meet our needs for expansion.
“This investment will allow for new capabilities for AstraZeneca in Ireland and support our global ambition to accelerate the development and delivery of life-changing medicines for more people affected by rare diseases.”
Back to Homepage
Back to Healthcare